Analyst Jonathan Wolleben lowers Altimmune’s price target to $14 from $15, maintains Outperform rating. Excited for pemvidutide Phase 2b data presentation at Liver Meeting with 48-week data on track for this quarter. Stay updated with real-time financial news on TheFly. Explore hot stock picks on TipRanks for insider trading insights. Learn more about ALT with Disclaimer & Disclosure information.

Read more at Yahoo Finance: Altimmune price target lowered to $14 from $15 at Citizens JMP